Histoserv, Inc.

Histoserv, Inc., a woman-owned, minority-owned (Subcontinent Asian American) small business based in Germantown, Maryland, provides specialized histology and neuropathological assessment services to the National Institutes of Health and its component institutes as a prime contractor exclusively — the company holds no subcontracting relationships and operates 100% as a prime across its 147 recent awards. Histoserv is a Subchapter S Corporation registered in SAM.gov since 2003; it competes in full-and-open procurements without set-aside designations, though most orders recognize its woman-owned and minority-owned status for evaluation credit.

Histoserv's capability portfolio centers on tissue processing, staining (hematoxylin and eosin, immunohistochemistry), paraffin embedding, sectioning, digital image scanning, and specialized neuropathological assays supporting biomedical research. Representative work includes a $215,567 Total Small Business set-aside purchase order from the National Institute on Aging (June 2026) for neuropathology characterization of 58 large-format human brain autopsy samples for the Brain Atlas Project, with firm fixed-price delivery of H&E staining on 928 tissue blocks and 30 immunohistochemical stains per sample using four government-specified antibodies; a $119,907 firm fixed-price purchase order from the National Institute of Mental Health (September 2026) for neuropathological assessment of aged donors in the Human Brain Collection Core; and a $84,650 purchase order from NIA (May 2022) for immunostaining of large human brain sections using the MARIC protocol. Recent work also includes immunohistochemistry analysis of 2,184 mice tissue samples, arterial plaque characterization, and microscopy support for NIH research into allergies, infectious diseases, genomics, and aging.

Customer concentration sits entirely within HHS/NIH. The top five funding entities account for 93% of combined potential value. The Office of Logistics and Acquisition Operations anchors the dollars — 13 awards valued at $10.1 million combined potential value — while the Office of the Director places the most awards by count (36 awards, $286 thousand combined potential value). The National Institute on Aging, NIH Clinical Center, and National Cancer Institute round out the active set. This concentration reflects Histoserv's footprint on two large NIH BPAs: a $10.0 million single-award Blanket Purchase Agreement with the Office of Logistics and Acquisition Operations (effective through March 31, 2027) that serves as an IDIQ vehicle for laboratory and testing services across multiple NIH institutes and centers, and a $40,000 single-award BPA with the National Institute of Biomedical Imaging and Bioengineering (through April 30, 2027). Task orders under the larger $10.0 million BPA dominate utilization; the source lists 31 task orders totaling $129 thousand from one predecessor BPA vehicle and 26 task orders valued at $456 thousand from another, indicating consistent multi-year ordering patterns across NIH institutes.

Activity has remained flat over the past five years — four to five awards annually from 2022 through 2025, with two awards recorded as of September 2026. Combined potential value across all 147 awards stands at $12.1 million, with $2.3 million obligated (19% of potential). Two awards face ultimate completion in the next twenty-four months, carrying combined potential value of $335 thousand and representing minimal recompete exposure in that window. Work is performed at the contractor's Germantown, Maryland facility and at NIH research locations including the NIH Clinical Center in Bethesda. The vendor's NAICS footprint is concentrated in Medical Laboratories (112 awards) with secondary activity in Testing Laboratories and Services (10 awards), consistent with its core tissue analysis and laboratory support mission.